Skip to content

Visual Assessment of DAILIES® AquaComfort Plus® for Astigmatism as Compared to 1-DAY ACUVUE® MOIST® for Astigmatism

DAILIES® AquaComfort Plus® Toric - Comparative Assessment of Visual and Mechanical Performance

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02071771
Enrollment
80
Registered
2014-02-26
Start date
2014-04-30
Completion date
2014-09-30
Last updated
2015-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism

Keywords

DACP Toric, DAILIES® AquaComfort Plus®, Astigmatism, Toric

Brief summary

The purpose of this study is to evaluate functional vision associated with rotational stability at blink of DAILIES® AquaComfort Plus® Toric (DACP T) compared to 1-DAY ACUVUE® MOIST® for Astigmatism (1DAM A).

Interventions

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must sign an Informed Consent document; * Wear toric soft contact lenses within the protocol-specified range; * Cylinder equal or higher than -0.75 diopters (D) in both eyes; * Have an acceptable fit with both study contact lenses; * Willing to wear lenses for a minimum of 5 days per week, 6 hours per day, every day, if possible; * Best corrected visual acuity (BCVA) of 20/30 Snellen; * Other protocol-specified inclusion criteria may apply.

Exclusion criteria

* Any ocular infection, inflammation, abnormality, or disease that would contraindicate contact lens wear; * Use of systemic or ocular medications that would contraindicate contact lens wear, as determined by the investigator; * Monocular (only 1 eye with functional vision) or fit with only 1 lens; * Require presbyopic correction; * Any ocular condition observed during examination at the enrollment visit; * History of herpetic keratitis, ocular surgery or irregular cornea; * Pregnant or lactating; * Participation in any clinical trial within 30 days of the enrollment visit; * Currently wearing Focus® DAILIES® Toric or 1-DAY ACUVUE® MOIST® for Astigmatism; * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
High Contrast Time Controlled Visual Acuity (TCVA) at Day 10Day 10, each productTCVA test was performed at 4 meters under high illumination (90%) using a Landolt ring test. For each acuity level, a series of single rings with gaps in one of four directions was presented and the percentage of correctly identified rings constituted the score. TCVA was measured in VA units and a higher TCVA value indicates an improvement in visual acuity. Both eyes contributed to the analysis.

Secondary

MeasureTime frameDescription
Lens Oscillation at Blink at Day 10Day 10, each productLens oscillation (rotational stability of the lens on the eye) at blink was video-recorded. Digital images were used to measure the rotational characteristics of the lenses and objectively measure the amplitude of the lens oscillation. A higher value indicates greater lens movement on the eye. This outcome measure was collected at one site only.

Participant flow

Recruitment details

Subjects were recruited from 1 study center located in the US and 1 study center located in the UK.

Pre-assignment details

This reporting group includes all enrolled participants, as treated. Note: 2 participants randomized to DACP T were exited prior to dispense due to unacceptable fit (1) and unavailable lens power (1).

Participants by arm

ArmCount
Overall
Nelfilcon A and Etafilcon A toric contact lenses worn during Period 1 and Period 2, as randomized, in a crossover assignment.
69
Total69

Withdrawals & dropouts

PeriodReasonFG000FG001
Period 1: First 10 DaysUnacceptable lens fit10
Period 1: First 10 DaysUnavailable lens power10

Baseline characteristics

CharacteristicOverall
Age, Continuous32.9 years
STANDARD_DEVIATION 9.4
Sex: Female, Male
Female
45 Participants
Sex: Female, Male
Male
24 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 790 / 78
serious
Total, serious adverse events
0 / 790 / 78

Outcome results

Primary

High Contrast Time Controlled Visual Acuity (TCVA) at Day 10

TCVA test was performed at 4 meters under high illumination (90%) using a Landolt ring test. For each acuity level, a series of single rings with gaps in one of four directions was presented and the percentage of correctly identified rings constituted the score. TCVA was measured in VA units and a higher TCVA value indicates an improvement in visual acuity. Both eyes contributed to the analysis.

Time frame: Day 10, each product

Population: This analysis group includes all randomized subjects who had no major protocol violations excluding those who met the critical deviation criteria as specified in the Deviations and Evaluability Plan.

ArmMeasureValue (MEAN)Dispersion
DACP THigh Contrast Time Controlled Visual Acuity (TCVA) at Day 100.02 VA unitsStandard Deviation 0.94
1DAM AHigh Contrast Time Controlled Visual Acuity (TCVA) at Day 100.04 VA unitsStandard Deviation 0.92
Secondary

Lens Oscillation at Blink at Day 10

Lens oscillation (rotational stability of the lens on the eye) at blink was video-recorded. Digital images were used to measure the rotational characteristics of the lenses and objectively measure the amplitude of the lens oscillation. A higher value indicates greater lens movement on the eye. This outcome measure was collected at one site only.

Time frame: Day 10, each product

Population: This analysis group includes all randomized subjects at the UK site with data at visit who had no major protocol violations excluding those who met the critical deviation criteria as specified in the Deviations and Evaluability Plan.

ArmMeasureGroupValue (MEAN)Dispersion
DACP TLens Oscillation at Blink at Day 10Left Eye2.1 degreesStandard Deviation 1
DACP TLens Oscillation at Blink at Day 10Right Eye2.1 degreesStandard Deviation 1
1DAM ALens Oscillation at Blink at Day 10Left Eye2.5 degreesStandard Deviation 0.8
1DAM ALens Oscillation at Blink at Day 10Right Eye2.7 degreesStandard Deviation 1.1

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026